Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) In Adults With Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Bevacizumab (Primary) ; Lomustine (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 27 Oct 2016 Status changed from active, no longer recruiting to completed.
- 29 Jan 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018 as reported by ClinicalTrials.gov.
- 02 Jun 2015 Interim results (n=70) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.